
专业尿路上皮癌帕博利珠单抗
恩福妥单抗加帕博利珠单抗对比化疗治疗未治疗局部晚期或转移性尿路上皮癌:EV-302 III期研究的患者报告结果
By MedXY|2025年10月1日
EV-302试验显示,恩福妥单抗加帕博利珠单抗在未治疗的晚期尿路上皮癌患者中,相较于含铂化疗,能改善生存率和生活质量。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.